A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
Bildiriler > Özet Bildiri · 2018
Yazarlar: Jonathan Wade Goldman, Julien Mazieres, Fabrice Barlesi, Koczywas Marianna, Konstantin H Dragnev, Tuncay GÖKSEL, Alexis B Cortot, Nicholas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvara Taus, Manuel Cobo, Karla Hurt, Alan Chiang, Hossein Anvar, William J John, Luis G PazAres
ASCO, Amerika Birleşik Devletleri, Uluslararası, Poster, Özet Bildiri, 2018-2018